OTC: CLVLY - Clinuvel Pharmaceuticals Limited

Rentabilité sur six mois: +2.63%
Secteur: Healthcare

Calendrier des promotions Clinuvel Pharmaceuticals Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Plus de détails
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA 0.0168
EV/EBITDA 98.24
ISIN US1887691038
Industry Biotechnology
P/BV 29.78
P/E 93.89
P/S 54.84
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.031
Див.доход ао 0.3347
Дивиденд ао 0.0478
Сайт https://www.clinuvel.com
Цена ао 9.03
Число акций ао 0.05182 млрд
Changement de prix par jour: 0% (9.75)
Changement de prix par semaine: +4.28% (9.35)
Changement de prix par mois: -3.66% (10.12)
Changement de prix sur 3 mois: -4.88% (10.25)
Changement de prix sur six mois: +2.63% (9.5)
Changement de prix par an: -2.6% (10.01)
Evolution du prix sur 3 ans: -68.54% (30.99)
Evolution du prix sur 5 ans: -57.42% (22.9)
Evolution des prix depuis le début de l'année: -5.06% (10.27)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 5.76 2
P/BV 2.5 6
P/E 14.26 8
EV/EBITDA 5.78 9
Total: 7.13

Efficacité

Nom Signification Grade
ROA, % 15.42 5
ROE, % 17.55 5
Total: 7.33

Dividendes

Nom Signification Grade
Div yield, % 0.3467 0.88
DSI 1 10
Total: 3.85

Devoir

Nom Signification Grade
Debt/EBITDA 0.0156 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 170.49 10
Rentabilité Ebitda, % 313.79 10
Rentabilité EPS, % 111.63 10
Total: 9.4
Plus de détails

Établissements Volume Partager, %
Trust For Professional Managers-PMC Diversified Equity Fund 4782 0.01



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1.86M 1963 (61 année)
Mr. Lachlan Hay Chief Operations Officer N/A
Mr. Malcolm Bull Head of Australian Operations & Investor Relations N/A
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs N/A
Dr. Azza Hamila Head of Quality Assurance & Drug Safety N/A
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. Chief Scientific Officer
Mr. Peter Vaughan Chief Financial Officer
Ms. Claire Newstead-Sinclair C.A. Company Secretary

Adresse: Australia, Melbourne. VIC, 535 Bourke Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.clinuvel.com